NCT03488628View on ClinicalTrials.gov

High-Flow Nasal Oxygen Therapy for Exacerbation of Chronic Pulmonary Obstructive Disease.

NARecruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

June 27, 2018

Primary Completion Date

July 27, 2026

Study Completion Date

July 27, 2026

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
OTHER

Noninvasive ventilation

Noninvasive ventilation delivered through a face mask, in alternace with satandard nasal oxygen therapy over the first 24 hours

OTHER

High-Flow Nasal Oxygen therapy

High-Flow Nasal Oxygen therapy delivered continuously over the first 24 hours by the AIRVO2® device (Fisher \& Paykel Healthcare,New Zealand) through nasal canula.

Trial Locations (1)

45067

RECRUITING

CHR d'Orléans, Orléans

All Listed Sponsors
lead

Centre Hospitalier Régional d'Orléans

OTHER